Efficacité clinique et biologique des traitements antirétroviraux : exemple de la cohorte ANRS 1215

Simple item page
dc.contributor.authorPierre De Beaudrap
dc.contributor.authorAssane Diouf
dc.contributor.authorKhady Niang
dc.contributor.authorK. Bousso Niang
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T16:00:00Z
dc.date.available2026-03-22T16:00:00Z
dc.date.issued2014
dc.descriptionCitaciones: 2
dc.description.abstractIn 1998, the cohort ANRS 1215 was launched in Senegal with one of the first African antiretroviral treatment programs. Four hundred forty four HIV-infected adults started on ART were included between 1998 and 2004, and followed up to 2010. Mortality before 6 months was 15.6/100 person-year (PY) and associated to the initial disease severity. It decreased to 3.36/100 PY thereafter. The cumulative risks of virologic failure at 60 months and of drug resistance at 48 months were 25% and 16%, respectively.
dc.identifier.doi10.1007/s13149-014-0352-y
dc.identifier.urihttps://doi.org/10.1007/s13149-014-0352-y
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/55655
dc.language.isofr
dc.publisherSpringer Science+Business Media
dc.relation.ispartofBulletin de la Société de pathologie exotique
dc.sourceInstitut de Recherche pour le Développement
dc.subjectCohort
dc.subjectMedicine
dc.subjectAntiretroviral therapy
dc.subjectHuman immunodeficiency virus (HIV)
dc.subjectCohort study
dc.subjectSida
dc.subjectDrug resistance
dc.subjectInternal medicine
dc.subjectPediatrics
dc.subjectViral disease
dc.titleEfficacité clinique et biologique des traitements antirétroviraux : exemple de la cohorte ANRS 1215
dc.typearticle

Files

Collections

Artículo Científico Publicado